Can cosentyx be used for ankylosing spondylitis treatment?

Yes—Cosentyx (secukinumab) is used to treat ankylosing spondylitis

Cosentyx (secukinumab) is approved for treating active ankylosing spondylitis in adults. It’s an IL-17A inhibitor used when symptoms have not responded adequately to other treatments or depending on a patient’s treatment plan.

How it fits into ankylosing spondylitis treatment plans

In practice, Cosentyx is used as a biologic option for active ankylosing spondylitis, typically after standard approaches (like NSAIDs) are insufficient, or when clinicians choose a biologic earlier based on disease severity and patient factors.

What patients usually ask next: who should consider it?

Patients considering Cosentyx for ankylosing spondylitis typically want to know whether they have active disease despite current therapy and whether they meet the prescribing criteria used in their country/health system (such as adult status and “active” disease definition).

Sources

No source links were provided in the prompt for Cosentyx and ankylosing spondylitis approval details.